Search Results - "Oerlemans, M. I. F."

Cardiac amyloidosis: the need for early diagnosis by Oerlemans, M. I. F. J., Rutten, K. H. G., Minnema, M. C., Raymakers, R. A. P., Asselbergs, F. W., de Jonge, N.

“…Amyloidosis is a collection of systemic diseases characterised by misfolding of previously soluble precursor proteins that become infiltrative depositions,…”
Get full text

Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker? by Tingen, H. S. A., Tubben, A., Bijzet, J., van den Berg, M. P., van der Meer, P., Houwerzijl, E. J., Muntinghe, F. L. H., van der Zwaag, P. A., Glaudemans, A. W. J. M., Oerlemans, M. I. F. J., Knackstedt, C., Michels, M., Hirsch, A., Hazenberg, B. P. C., Slart, R. H. J. A., Nienhuis, H. L. A.

“…Purpose There is a need for early quantitative markers of potential treatment response in patients with hereditary transthyretin (ATTRv) amyloidosis to guide…”
Get full text

Characteristics and outcomes of COVID-19 in heart transplantation recipients in the Netherlands by Muller, S. A., Manintveld, O. C., Szymanski, M. K., Damman, K., van der Meer, M. G., Caliskan, K., van Laake, L. W., Oerlemans, M. I. F. J.

“…Background Immunocompromised patients are at high risk of complicated severe acute respiratory coronavirus 2 infection. The aim of this retrospective study was…”
Get full text

A routine intervention in a highly unusual vessel by Gasecka, A., Voskuil, M., de Waal, E. E. C., Oerlemans, M. I. F. J., Ramjankhan, F., van Laake, L. W., Kraaijeveld, A. O.

Get full text

Morning pulmonary artery pressure measurements by CardioMEMS are most stable and recommended for pressure trends monitoring by Crnko, S., Brugts, J. J., Veenis, J. F., de Jonge, N., Sluijter, J. P. G., Oerlemans, M. I. F., van Laake, L. W.

“…Aims The CardioMEMS HF system is used to measure pulmonary artery (PA) pressures of patients with heart failure (HF). The goal of this study was to determine…”
Get full text

Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation by Noort, W. A., Oerlemans, M. I. F. J., Rozemuller, H., Feyen, D., Jaksani, S., Stecher, D., Naaijkens, B., Martens, A. C., Bühring, H. J., Doevendans, P. A., Sluijter, J. P. G.

“…Although mesenchymal stromal cells (MSCs) have been applied clinically to treat cardiac diseases, it is unclear how and to which extent transplanted MSCs exert…”
Get full text

Listing criteria for heart transplantation in the Netherlands by de Jonge, N., Damman, K., Ramjankhan, F. Z., van der Kaaij, N. P., van den Broek, S. A. J., Erasmus, M. E., Kuijpers, M., Manintveld, O., Bekkers, J. A., Constantinescu, A. C., Brugts, J. J., Oerlemans, M. I. F., van Laake, L. W., Caliskan, K.

“…The updated listing criteria for heart transplantation are presented on behalf of the three heart transplant centres in the Netherlands. Given the shortage of…”
Get full text

Outcome of mechanical circulatory support at the University Medical Centre Utrecht by Felix, S. E. A., Ramjankhan, F. Z., Buijsrogge, M. P., Jacob, K. A., Asselbergs, F. W., Oerlemans, M. I. F., Kirkels, J. H., van Laake, L. W., Oppelaar, A. M. C., Suyker, W. J. L., de Jonge, N.

“…Background The prevalence of heart failure (HF) is increasing substantially and, despite improvements in medical therapy, HF still carries a poor prognosis…”
Get full text

Circulating MicroRNAs as Novel Biomarkers for the Early Diagnosis of Acute Coronary Syndrome by Deddens, J. C., Colijn, J. M., Oerlemans, M. I. F. J., Pasterkamp, G., Chamuleau, S. A., Doevendans, P. A., Sluijter, J. P. G.

“…Small non-coding microRNAs (miRNAs) are important physiological regulators of post-transcriptional gene expression. miRNAs not only reside in the cytoplasm but…”
Get full text

Human in vitro disease modeling of ATTR cardiac amyloidosis by Qin, J, Dokter, I, Qiang, Y, Lei, Z, Sluijter, J P G, Oerlemans, M I F, Van Mil, A

“…Abstract Background Amyloidosis is a systemic protein-folding disorder characterized by extracellular misfolded fibrillar protein aggregates that are insoluble…”
Get full text

One-year mortality after a first visit to a cardiology outpatient clinic: a useful performance indicator? by Oerlemans, M. I. F. J., Lok, D. J. A., Cornel, J. H., Mosterd, A.

“…Purpose In 2003 the Dutch Health Care Inspectorate introduced performance indicators to monitor and compare quality of care in Dutch hospitals. In 2007, the…”
Get full text

Clinical relevance and outcome of routine endomyocardial biopsy to detect rejection after heart transplantation by Kieviet, L, Szymanski, M K, Van Der Meer, M G, Van Der Kaaij, N P, De Jonge, N, Van Laake, L W, Oerlemans, M I F

“…Abstract Background After heart transplantation (HTx), endomyocardial biopsies (EMBs) are the gold standard to monitor cardiac allograft rejection. However, a…”
Get full text

Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis by Muller, S A, Peiro-Aventin, B, Biagioni, G, Tini, G, Saturi, G, Knackstedt, C, Dobner, S, Michels, M, Merlo, M, Nitsche, C, Longhi, S, Musumeci, B, Cappelli, F, Garcia-Pavia, P, Oerlemans, M I F J

“…Abstract Background The 2021 European Society of Cardiology (ESC) screening recommendations for individuals carrying a pathogenic transthyretin amyloidosis…”
Get full text

CMR predictors of acute right heart failure after LVAD implantation by Coraducci, F, Fedele, D, De Zan, G, Costantini, P, Broekhuizen, L N, Teske, A J, Cramer, M J, Van Laake, L W, Oerlemans, M I F, Van Hout, G P J, Pizzi, C, Dello Russo, A, Van Der Bilt, I, Van Der Harst, P, Guglielmo, M

“…Abstract Background Acute right heart failure (RHF) is one of the most dangerous complications after placement of left ventricular assisted device (LVAD),…”
Get full text